Trump Administration Announces Major Price Cuts for GLP-1 Weight Loss Drugs Through TrumpRx Initiative
核心洞察
President Trump announced significant price reductions for GLP-1 (搜索) drugs including Wegovy and Ozempic, with monthly costs dropping to $245-250 for Medicare patients starting in 2026.
The TrumpRx initiative eliminates pharmacy benefit managers (PBMs) as intermediaries, allowing direct-to-consumer pricing that Cuban says enables drugmakers to maintain profitability while reducing costs.
Eli Lilly and Novo Nordisk committed $27 billion and $20 billion respectively in US manufacturing investments to support the reduced pricing structure.
President Trump announced Thursday a landmark agreement with pharmaceutical giants Eli Lilly and Novo Nordisk to dramatically reduce prices for popular GLP-1 (搜索) weight loss and diabetes medications through the new TrumpRx initiative. The deal will make Wegovy available for $250 per month and other GLP-1 drugs for $245 monthly for Medicare patients, with a $50 co-pay, beginning in 2026.
The announcement fulfills Trump's October promise to cut Ozempic costs from around $1,000 to $150, though the $150 price point applies specifically to oral GLP-1 (搜索) formulations. Chris Klomp, deputy administrator at the Centers for Medicaid and Medicare Services (搜索), confirmed that "starting doses" for oral drugs like a potential Wegovy pill and Eli Lilly's orforglipron would be priced at $149 if approved.
Eliminating Healthcare Middlemen
The TrumpRx model mirrors the direct-to-consumer approach championed by Mark Cuban through his Cost Plus Drugs (搜索) pharmacy. Cuban, a longtime Trump critic who has praised this initiative, explained that the dramatic price reductions are possible because the program eliminates pharmacy benefit managers (PBMs) as intermediaries.
"Anything that impacts the middleman, I'm a fan of," Cuban told Business Insider Thursday. "The big brand pharmaceutical manufacturers recognize they make more money with net pricing. That's why Lilly and Novo do their direct thing, and it's half the price, or less than half the price, of what a corporate sponsor is paying for their GLP-1 (搜索), even after rebates."
PBMs traditionally negotiate with drug manufacturers to include medications in their formularies and secure patient coverage. This opaque process creates wildly different pricing depending on insurance coverage, making it difficult for consumers to predict prescription costs until reaching the pharmacy counter.
Manufacturing Investments Enable Lower Pricing
Both Eli Lilly and Novo Nordisk attended the White House announcement, with their substantial US manufacturing commitments helping facilitate the reduced pricing. Eli Lilly committed $27 billion while Novo Nordisk pledged $20 billion in domestic manufacturing investments.
"That's all? That's peanuts," Trump commented regarding their manufacturing investments.
The companies have already established direct-to-consumer websites selling GLP-1 (搜索) drugs at $350-500 monthly depending on dosage—representing more than 50% off list prices even before the TrumpRx initiative.
Cuban's Parallel Cost-Cutting Initiative
Coinciding with Trump's announcement, Cuban's Cost Plus Drugs (搜索) revealed its own major price reduction for Stelara, an autoimmune injectable medication. The pharmacy will offer the generic version Starjemza (搜索) for approximately $1,400 annually, down from Stelara's roughly $80,000 yearly cost.
This represents Cuban's latest effort to eliminate PBMs from healthcare pricing. His Cost Plus Drugs (搜索) operates on "net pricing"—providing transparent, fully negotiated prices for all customers rather than using inflated list prices subject to middleman negotiations.
Industry Transformation Toward Direct Sales
Cuban describes both initiatives as part of a "farm-to-table" transformation in prescription drug pricing, featuring clear price tags and direct-to-consumer sales models.
"TrumpRx fits that mold," Cuban said. "It's not that the brands don't want to sell to us—it's that they're used to selling through middlemen. Now, with direct-to-consumer happening more and more, or farm-to-table, I think that's going to start to change."
The billionaire entrepreneur noted that pharmaceutical companies are increasingly willing to engage in direct conversations about pricing. "We're having a lot of really good conversations directly with pharmaceutical brands," Cuban said.
Cuban's ultimate goal involves making every brand-name medication available with transparent pricing, eliminating the uncertainty that currently characterizes prescription drug costs for American consumers.